Kura Oncology Files 8-K

Ticker: KURA · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1422143

Kura Oncology, INC. 8-K Filing Summary
FieldDetail
CompanyKura Oncology, INC. (KURA)
Form Type8-K
Filed DateOct 16, 2025
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, corporate-event, filing

TL;DR

Kura Oncology filed an 8-K on 10/16/25 for an event on 10/15/25. Check it out.

AI Summary

Kura Oncology, Inc. filed an 8-K on October 16, 2025, reporting an event that occurred on October 15, 2025. The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits'. The company's principal executive offices are located at 4930 Directors Place, Suite 500, San Diego, CA 92121.

Why It Matters

This 8-K filing indicates a significant corporate event or update from Kura Oncology, Inc., requiring immediate disclosure to investors.

Risk Assessment

Risk Level: medium — An 8-K filing signifies a material event that could impact the company's stock price, requiring investor attention.

Key Players & Entities

FAQ

What specific event triggered this 8-K filing for Kura Oncology, Inc. on October 15, 2025?

The filing does not specify the exact event, only that it occurred on October 15, 2025, and is categorized under 'Other Events' and 'Financial Statements and Exhibits'.

What is the primary business of Kura Oncology, Inc. based on the SIC code?

Kura Oncology, Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, with SIC code 2834.

When was Kura Oncology, Inc. incorporated and in which state?

Kura Oncology, Inc. was incorporated in Delaware.

What is the IRS Employer Identification Number (EIN) for Kura Oncology, Inc.?

The IRS Employer Identification Number (EIN) for Kura Oncology, Inc. is 61-1547851.

What was the former name of Kura Oncology, Inc. and when did the name change occur?

The former name was ZETA ACQUISITION CORP III, and the date of the name change was December 27, 2007.

Filing Stats: 590 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-10-16 16:11:18

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Kura Oncology, Inc. 2023 Inducement Option Plan, as amended, and Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise thereunder. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kura Oncology, Inc. Date: October 16, 2025 By: /s/ Teresa Bair Teresa Bair Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing